PMID- 16284959
OWN - NLM
STAT- MEDLINE
DCOM- 20060418
LR  - 20160303
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 118
IP  - 8
DP  - 2006 Apr 15
TI  - T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma 
      of the oropharynx.
PG  - 1984-91
AB  - Squamous cell carcinomas of the oropharynx (SCCO) are often infected with 
      oncogenic human papilloma virus (HPV) subtype 16. To determine the frequency of T 
      cells specific for human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7 
      protein-derived epitopes, tetramer analysis was performed using peripheral blood 
      lymphocytes of 20 HLA-A2.1+ patients and 20 HLA-A2.1+ healthy individuals. 
      Tetramers specific for 3 HPV16 peptides (E711-20, E782-90 and E786-93), an 
      influenza matrix peptide (a model recall antigen) or an HIV reverse transcriptase 
      peptide (a model novel antigen) were used in multicolor flow analysis. The 
      HPV-specific T-cell frequencies were correlated with the HPV16 E7 and p16 status 
      in tumor sections. In vitro stimulation (IVS) with autologous dendritic cells 
      (DC) pulsed with HPV16 E7 epitopes was performed to demonstrate proliferation and 
      antitumor activity of the HPV-responsive T cells. Frequencies of CD8+ T cells 
      specific for HPV16 E7 peptides were not significantly different in patients with 
      SCCO relative to normal donors. However, patients with tumors expressing HPV16 E7 
      (60%) and p16 (50%) had an increased frequency (p<0.05) of T cells specific for 
      the E711-20 epitope compared to those with tumors negative for both markers. 
      HPV16 E711-20 and HPV16 E786-93 specific T cells were expandable upon IVS with 
      cognate peptide-pulsed DC and were reactive against peptide-pulsed targets or, in 
      case of the E711-20 epitope-specific T cells, against HPV16 E7 expressing CaSki 
      cell line. Thus, in patients with HPV16+ SCCO, precursor T cells specific for 
      E711-20 epitope are present (1/3,947) in the circulation, are responsive to 
      stimulation with the cognate viral peptide and recognize in vitro HPV16 E7+ tumor 
      cells. Further studies have to elucidate why those T cells are unable to 
      eliminate the tumor in vivo and this might also allow for finding potential 
      strategies that will increase the chances of developing a future HPV-based 
      vaccine in patients with SCCO.
CI  - Copyright (c) 2005 Wiley-Liss, Inc.
FAU - Hoffmann, Thomas K
AU  - Hoffmann TK
AD  - Department of Otorhinolaryngology, University of Duesseldorf, Germany. 
      tkhoffmann@uni-duesseldorf.de
FAU - Arsov, Christian
AU  - Arsov C
FAU - Schirlau, Kerstin
AU  - Schirlau K
FAU - Bas, Murat
AU  - Bas M
FAU - Friebe-Hoffmann, Ulrike
AU  - Friebe-Hoffmann U
FAU - Klussmann, Jens Peter
AU  - Klussmann JP
FAU - Scheckenbach, Kathrin
AU  - Scheckenbach K
FAU - Balz, Vera
AU  - Balz V
FAU - Bier, Henning
AU  - Bier H
FAU - Whiteside, Theresa L
AU  - Whiteside TL
LA  - eng
GR  - P0-1 DE12321/DE/NIDCR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Antigens, Viral)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Epitopes, T-Lymphocyte)
SB  - IM
MH  - Antigens, Viral
MH  - Cancer Vaccines
MH  - Carcinoma, Squamous Cell/genetics/*immunology/*virology
MH  - Dendritic Cells
MH  - Epitopes, T-Lymphocyte/*immunology
MH  - Female
MH  - Human papillomavirus 16/*immunology/pathogenicity
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oropharyngeal Neoplasms/genetics/*immunology/*virology
MH  - Papillomavirus Infections/*complications
EDAT- 2005/11/15 09:00
MHDA- 2006/04/19 09:00
CRDT- 2005/11/15 09:00
PHST- 2005/11/15 09:00 [pubmed]
PHST- 2006/04/19 09:00 [medline]
PHST- 2005/11/15 09:00 [entrez]
AID - 10.1002/ijc.21565 [doi]
PST - ppublish
SO  - Int J Cancer. 2006 Apr 15;118(8):1984-91. doi: 10.1002/ijc.21565.